Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) will likely be issuing its Q4 24/25 quarterly earnings data before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of $0.20 per share and revenue of $83.70 billion for the quarter.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, analysts expect Dr. Reddy's Laboratories to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Dr. Reddy's Laboratories Stock Up 1.2 %
RDY stock traded up $0.17 during midday trading on Friday, reaching $14.00. The company had a trading volume of 1,236,700 shares, compared to its average volume of 1,477,270. The company has a 50 day moving average of $13.23 and a two-hundred day moving average of $14.14. The company has a market capitalization of $11.69 billion, a P/E ratio of 22.29 and a beta of 0.51. Dr. Reddy's Laboratories has a 1 year low of $12.26 and a 1 year high of $16.89. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02.
Dr. Reddy's Laboratories Company Profile
(
Get Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Read More
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
